Phase 2 N=15 Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Hepatitis C
Primary: Intrahepatic and Plasma HCV Viral Kinetics — 6.5; 4.9; 3.2; 4.2 log transformed copies/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Malignant Germ Cell Tumor · Childhood Malignant Ovarian Germ Cell Tumor
Primary: Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 12; 8 participants
Phase 2 N=41 Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
Squamous Cell Carcinoma
Primary: Response Rate — .35; .22 proportion of participants
Phase 2 N=130 Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIB Non-Small Cell Lung Cancer AJCC v7 · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: 18 Week Progression-free Survival (PFS) Rate — 54; 37; 48 percentage of participants
Phase 2 N=177 Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Breast Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1 — 12; 2; 11; 0 Participants
Phase 2 N=100 A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Lymphoma, B-Cell
Primary: Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment — 55.0 percentage of participants
Phase 2 N=21 An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of PD-0332991: Phase 1 — NA; 100 milligram (mg)
Phase 2 N=60 Green Tea Lozenges for the Management of Dry Mouth
Xerostomia · Sjogren Syndrome · Dry Mouth
Primary: Change in Salivary Flow From Baseline — 0.17; 0.10; 0.66; 0.04 ml/min
Phase 2 N=66 Development of Positive Psychotherapy for Smoking Cessation
Smoking
Primary: 7-day Point Prevalence Smoking Abstinence at 8 Weeks — 40.0; 25.8 percentage of participants abstinent — p=.22
Phase 2 N=410 Yoga in Treating Sleep Disturbance in Cancer Survivors
Fatigue · Cancer · Sleep Disorders
Primary: Mean Post-Pre Change for the Pittsburgh Sleep Quality Inventory (PSQI) — -1.96; -1.07 units on a scale — p=0.009
Phase 2 N=58 Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 11-month Survival Rate — 70 percentage of participants
Phase 2 N=90 Effects of Acupuncture in the Treatment of Infant Colic
Infant Colic
Primary: Change in Crying Time Per 24 Hour Period. — 220; 212; 230; 186 minutes crying time pr 24 hour
Phase 2 N=254 Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: ACR Efficacy Criteria — 63; 57; 57; 61 participants
Phase 2 N=38 Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Clostridium Difficile-associated Diarrhea
Primary: Number of Participants With Adverse Events. — 28 participants
Phase 2 N=11 TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Hepatocellular Carcinoma · Hepatocellular Cancer · Carcinoma, Hepatocellular
Primary: Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC). — 12 Weeks